108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
乳腺上皮肌上皮癌能从 TROP2 抗体药物偶联物中获益吗？
Authors Zhao Q, Luo X, Xing H, Jiang C, Ma J, Tang L
Received 11 June 2025
Accepted for publication 29 August 2025
Published 12 September 2025 Volume 2025:18 Pages 1013—1025
DOI https://doi.org/10.2147/OTT.S540295
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Qing Zhao,1,* Xiao Luo,1,* Hua Xing,1 Chengwei Jiang,2 Jingchao Ma,2 Lu Tang1
1Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 2Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lu Tang, Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Tel/Fax +86 431-84995495, Email tanglu@jlu.edu.cn
Abstract: Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.
Keywords: epithelial-myoepithelial carcinoma, breast cancer, TROP2 antibody-drug conjugate, malignant epithelial myoepithelial carcinoma, treatment
1Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 2Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lu Tang, Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Tel/Fax +86 431-84995495, Email tanglu@jlu.edu.cn
Abstract: Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.
Keywords: epithelial-myoepithelial carcinoma, breast cancer, TROP2 antibody-drug conjugate, malignant epithelial myoepithelial carcinoma, treatment